# NRG-GY036 (NCT06580314)

> Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06580314
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: NRG Oncology
- Conditions: Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor; FIGO Stage III Ovarian Cancer 2014; FIGO Stage IV Ovarian Cancer 2014; Ovarian Carcinoma; Ovarian Carcinosarcoma; Ovarian High Grade Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma
- Interventions: Bevacizumab; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Olaparib
- Enrollment: 880
- Primary outcome: Progression free survival (PFS) at least 360 days after randomization (PFS360)

## Indexed commentary on NRG-GY036 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 10
- Podcasts: 4
- X threads: 4
- Bluesky threads: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nrg-gy036-nct06580314

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06580314", "email": "<work email>"}; the inbox owner confirms by the emailed link.